Clinical Efficacy and Safety Analysis of 308nm Excimer Ultraviolet Light Combined with Carbon Dioxide Fractional Laser in the Treatment of Refractory Vitiligo

Abstract

This paper aims to explore the clinical effect and safety of combined application of 308 nm excimer ultravioletlight and carbon dioxide fractional laser in the treatment of refractory vitiligo. The study was carried out from January 2020 to December 2022. 60 patients with refractory vitiligo were selected and divided into the study group (n = 30) and the control group (n = 30) through the lottery method of medical record envelopes. The patients in the control group were treated with 308 nm excimer ultraviolet light, and the patients in the study group were treated with 308 nm excimer ultraviolet light combined with carbon dioxide fractional laser treatment. The clinical effective rate, leukoplakia area, IgG level, and incidence of adverse reactions were compared between the two groups. The clinical effective rate of the study group was higher than that of the control group (P < 0.05). After treatment, the leukoplakia area of the study group was lower than that of the control group (P < 0.05), and the IgG level of the study group was lower than that of the control group (P < 0.05). The incidence of adverse reactions in the study group was lower than that in the control group (P < 0.05). The combined application of 308 nm excimer ultraviolet light and carbon dioxide fractional laser therapy for patients with refractory vitiligo has a significant effect, can reduce the area of leukoplakia and IgG levels, and has high treatment safety, which can be widely applied in clinical practice.